Skip to content
Disclosery

EXANE DERIVATIVES: KRC position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on KRC, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 0 KRC shares at 2022-03-31 per its 13F-HR filed 2022-04-22.

the latest 13F is the newest step

  1. period ended2022-03-31
    13F 0 shares
    Change vs previous 13F -2,748 shares

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2021-12-31
    13F 2,748 shares
    Change vs previous 13F +266 shares

    0.04% of the 13F portfolio, value $182,625.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-09-30
    13F 2,482 shares
    Change vs previous 13F +2,482 shares

    0.04% of the 13F portfolio, value $164,327.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-03-31
    13F 0 shares
    Change vs previous 13F -5 shares

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  5. period ended2020-12-31
    13F 5 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $287.

    13F-HR 0001623883-21-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2020-09-30
    13F/A 5 shares
    Change vs previous 13F not available

    <0.01% of the 13F portfolio, value $260.

    13F-HR/A 0001623883-20-000010 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).